CAMBRIDGE, Mass. (WBZ NewsRadio) Cambridge-based Moderna announced Tuesday it will begin giving doses to the participants in a children-only vaccine study.
The study, called the "KidCOVE" study, will look at the vaccine's effectiveness in children aged 6 months to 12 years.
The KidCOVE study will include a total of 6,750 participants.
Moderna is partnering with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) in conducting the study.
Moderna's COVID-19 vaccine is already approved for adults 18 and older.
WBZ's Laurie Kirby (@LaurieWBZ) has more: